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Abstract
Background. When patients are admitted onto psychiatric wards, sleep problems are highly
prevalent. We carried out the first trial testing a psychological sleep treatment at acute admis-
sion (Oxford Ward sLeep Solution, OWLS).
Methods. This assessor-blind parallel-group pilot trial randomised patients to receive sleep
treatment at acute crisis [STAC, plus standard care (SC)], or SC alone (1 : 1). STAC included
cognitive–behavioural therapy (CBT) for insomnia, sleep monitoring and light/dark exposure
for circadian entrainment, delivered over 2 weeks. Assessments took place at 0, 2, 4 and 12
weeks. Feasibility outcomes assessed recruitment, retention of participants and uptake of
the therapy. Primary efficacy outcomes were the Insomnia Severity Index and Warwick–
Edinburgh Mental Wellbeing Scale at week 2. Analyses were intention-to-treat, estimating
treatment effect with 95% confidence intervals.
Results. Between October 2015 and July 2016, 40 participants were recruited (from 43
assessed eligible). All participants offered STAC completed treatment (mean sessions
received = 8.6, S.D. = 1.5). All participants completed the primary end point. Compared with
SC, STAC led to large effect size (ES) reductions in insomnia at week 2 (adjusted mean dif-
ference −4.6, 95% CI −7.7 to −1.4, ES −0.9), a small improvement in psychological wellbeing
(adjusted mean difference 3.7, 95% CI −2.8 to 10.1, ES 0.3) and patients were discharged 8.5
days earlier. One patient in the STAC group had an adverse event, unrelated to participation.
Conclusions. In this challenging environment for research, the trial was feasible. Therapy
uptake was high. STAC may be a highly effective treatment for sleep disturbance on wards
with potential wider benefits on wellbeing and admission length.
Introduction
It is almost ubiquitous for patients admitted at acute crisis to a psychiatric hospital to have
sleep disturbance. Around eight out of 10 patients report clinically significant insomnia
(Haynes et al. 2011). A negative correlation has been found between sleep duration at
admission to a psychiatric ward and subsequent length of time in hospital (Langsrud
et al. 2016). There is increasing awareness of the importance of sleep to mental health
(Boyce, 2015; Freeman et al. 2017). Whilst previously subsumed as a symptom of mental
illness, changes in classification now recommend diagnosing and treating sleep disorders
(e.g. insomnia) as an independent clinical problem (American Psychiatric Association,
2013). Treatment of insomnia has been shown to lessen psychotic experiences (Freeman
et al. 2017), mania (Harvey et al. 2015), depression (Manber et al. 2008; Ye et al. 2015)
and anxiety (Espie et al. 2012; Ye et al. 2015). Treatment of insomnia in psychiatric inpa-
tients may therefore be an important clinical target to aid recovery, irrespective of psychi-
atric diagnosis.
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Psychiatric wards bring unique challenges to the sleep system.
Staff risk management observations of patients often require a
light to be turned on periodically throughout the sleep period.
The environment can be noisy. In the daytime, limited access to
natural daylight leaves the circadian system vulnerable to dysregu-
lation. Stress from being held in hospital under a section of the
Mental Health Act or a coercive route to hospital may exacerbate
night-time hyper-arousal. Stabilising sleep may bring benefits for
recovery, but interventions such as cognitive–behavioural therapy
(CBT) for insomnia require adapting to manage these challenges.
CBT is associated with moderate-to-large effect size improve-
ments in insomnia symptoms (Irwin et al. 2006) and is the
recommended first-line treatment for persistent insomnia in
international clinical guidelines (National Institute for Health
and Care Excellence, 2015; Qaseem et al. 2016). Two pilot rando-
mised controlled trials (RCTs) have shown positive results for
adapted CBT for insomnia protocols in populations with severe
mental illness. Large effect size improvements in insomnia symp-
toms were found in patients with persistent delusions and hallu-
cinations in the context of schizophrenia and related diagnoses
(Freeman et al. 2015). This protocol particularly took into
account circadian rhythm disruption, which is common in
patients with schizophrenia (Waite et al. 2015). Similarly, offering
adapted CBT for insomnia to patients in the euthymic phase of
bipolar affective disorder led to reduced insomnia symptoms
and fewer days in a bipolar episode (Harvey et al. 2015).
However, CBT for insomnia has not yet been adapted or tested
for patients experiencing an acute episode of severe mental illness
whilst in hospital.
Increasing the effectiveness of inpatient treatment works
towards the goal of each admission being as ‘short as possible,
minimising disruption to life, as well as cost’ (Crisp, 2015). In
the UK, inpatient services are the highest area of spending,
using over £1 billion of the £5.5 billion budget for adult mental
health (Mental Health Strategies, 2012). Despite this spending,
there is continued pressure for acute inpatient care beds. The
average ward in England is running over maximum capacity
(Crisp, 2015). This results in patients travelling long distances
from home to receive treatment (Crisp et al. 2016). Targeted
interventions that reduce the length of an admission would
have clear benefits for both patients and services.
The current study builds upon the work testing adapted proto-
cols for treating insomnia in patients experiencing psychosis
(Freeman et al. 2015) and bipolar disorder (Harvey et al. 2015)
and uncontrolled studies in inpatient settings (Morin et al.
1990; Haynes et al. 2011; Breitstein et al. 2014). Our sleep
treatment at acute crisis (STAC) included CBT for insomnia
with three adaptations: (i) enhanced light/dark exposure to
stabilise circadian rhythms, (ii) discussion of sleep and activity
levels, monitored using ambulatory devices, to engage patients
in their treatment and boost motivation and (iii) delivery of the
intervention within a 2-week window to ensure all patients receive
help.
The study was designed as a pilot RCT. The primary objective
was to assess trial procedures on an inpatient ward. Specifically,
the aim was to assess recruitment and retention rates, and uptake
of the therapy. The secondary objective was to estimate the treat-
ment effect and confidence intervals, compared with standard
care (SC) to inform future trials. The sleep treatment was
expected to result in quicker and fuller recovery from insomnia
and enhance psychological wellbeing.
Methods
Study design and participants
This parallel-group assessor-blind pilot RCT tested STAC, in add-
ition to SC, v. SC alone. Recruitment took place on one 18-bed
male only psychiatric inpatient ward (Vaughan Thomas ward)
in the Oxford Health National Health Service (NHS)
Foundation Trust, UK. The ward treats adult men, the majority
of whom are admitted during an acute episode of psychosis or
bipolar affective disorder. Patients sleep in individual bedrooms
and are monitored throughout the night by the staff to ensure
their safety. The frequency varies from hourly to constant obser-
vation, dependent on the individual assessment of risk. Study
inclusion criteria were: self-reported symptoms of insomnia [a
score of 8 on the Insomnia Severity Index (ISI)], wanting help
to improve sleep, willing and able to give informed consent to
participate (assessed according to the Mental Capacity Act,
2005) and willing to allow the community care team to be notified
of trial participation. Exclusion criteria were: a planned discharge
or transfer date within 14 days of the baseline, the patient’s home
residence was outside the geographical area covered by the Oxford
Health NHS Foundation Trust, a command of English language
inadequate for psychological therapy or completing assessments
and a diagnosis of learning disability or organic syndrome.
Patient enrolment was conducted by one graduate psychologist
(JM). The week 2 assessment was the primary end point. No
changes were made to the design or outcome measures after com-
mencement of the trial.
The trial received ethical approval from the NHS Research
Ethics Committee East Midlands, Leicester – Central (15/EM/
0341). The trial was registered (ISRCTN15324584). All patients
provided written informed consent.
Randomisation and blinding
Patients were randomly assigned to receive either STAC in add-
ition to SC or SC alone (1 : 1). The randomisation process was
made clear to patients in the participant information sheet,
prior to the consent process. The randomisation schedule was
developed by the University of Oxford Primary Care Clinical
Trials Unit using a web-based randomisation system. Minimisation
randomisation was used with an 80% chance of selecting the
minimising group. Minimisation balanced groups by stratifying
on the ISI (symptoms of insomnia, score 0–14 v. insomnia dis-
order, score >14), the Warwick–Edinburgh Mental Wellbeing
Scale (WEMWBS; low wellbeing, score 0–35 v. high wellbeing,
score 36–70) and participant diagnosis made by the ward consult-
ant psychiatrist (non-affective psychotic disorder, affective dis-
order or ‘other’).
Research assessors (JM and StR) were blind to treatment allo-
cation. The trial therapists (LI, BS and JB) informed the patients
of the outcome of randomisation to maintain allocation conceal-
ment. Precautionary measures to prevent unblinding included
research assessors and trial therapists block booking separate
times to be on the ward, patients were reminded about the
importance of unbiased assessments (blinding), research assessors
did not look at the patient clinical notes after randomisation had
taken place and the ward staff were regularly reminded of the
importance of blinding via meetings, posters and leaflets. In the
case of an unblinding, an alternative research assessor (blind to
allocation) was used. This happened nine times in total, eight
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times at the 2-week assessment and once at the 4-week assess-
ment. Every assessment was completed by an assessor who was
blind to treatment allocation. Measures were also taken to prevent
contamination between the intervention and control groups.
Participants in the intervention group were asked not to discuss
the therapy with other patients and the staff were also told
about the potential implications of contamination for the trial
results.
Procedures
STAC was provided by a clinical psychologist (LI, BS or JB) in
one-to-one sessions with each patient. Treatment took place on
the ward, in a local clinic room, or the local community whilst
using ward leave. BS and DF provided supervision. STAC was
delivered over a 2-week therapy window. Five sessions were
defined as a minimum dose (to include both formulation and
completion of at least one active therapy technique). The fre-
quency and duration of sessions were flexible depending on the
patient preference and clinical presentation.
The key therapeutic techniques were adapted CBT for insomnia.
This was supplemented with light/dark exposure for circadian
entrainment. Wrist-worn fitness trackers (Basis Peak watch) were
used as a therapy tool for assessment, to inform the development
of a collaborative sleep plan and to boost motivation. These watches
report individual sleep periods, activity levels and heart rate, which
are synced to an iOS application. The CBT for insomnia treatment
techniques was taken from three main sources (Espie, 2010; Kaplan
& Harvey, 2013; Waite et al. 2015). The intervention was written
into manual style booklets. These were shared with the patients.
One manual was used to guide each treatment session. Session 1
included psychoeducation, assessment and goal setting. The focus
of subsequent sessionswas chosenbased on the keymaintenance fac-
tors identified in session 1. Treatment techniques included: setting a
consistent sleep window, stimulus control, boosting circadian zeitge-
bers (light/dark,meals and timing of activity), wind-down (including
relaxation) and rise routines, strategies to manage night-time worry
and voices, and sleep hygiene. The final session was always relapse
management, including planning sleep strategies for use upon
discharge.
Key adaptations to the CBT for insomnia protocol for this
population included: (i) a rationale of boosting sleep as a tool
for recovery; (ii) delivering the intervention intensively over a
14-day therapy window to ensure that patients received a full
dose prior to discharge; (iii) stimulus control was completed
within the patient bedrooms, whereby a patient was encouraged
to leave the bed if unable to sleep and sit instead on a bean
bag; (iv) behavioural experiments to test beliefs about the use of
daytime sleep to combat fatigue (common due to sedative medi-
cation or depressive symptoms) and (v) practical strategies to
reduce the impact of night-time observations from the staff.
Principles of sleep restriction informed the intervention. Time
spent in bed was limited (particularly during the daytime and
early evening), and a consistent sleep window was collaboratively
set to ensure optimal sleep pressure each night. However, this was
achieved by setting the goal sleep window (often 7–8 h) and
ensuring that the window was timed in line with the circadian
preference (i.e. a ‘morning type’ typically had an earlier sleep win-
dow than an ‘evening type’). The sleep window was not set to less
than the goal sleep duration.
Exposure to light/dark therapy was used according to a clinical
manual (Wirz-Justice et al. 2013). We used light to shift circadian
rhythms and/or boost morning arousal. Our preference was for
timed exposure to natural daylight outdoors. Where access to nat-
ural daylight was not possible, due to patient illness or restricted
ward leave, we used Lumie Brazil light boxes, which emit 10 000
lux of light at a distance of 35 cm. Low light levels in the evening
period were emphasised for all patients to strengthen circadian
rhythms, but particularly for patients with a diagnosis of bipolar
affective disorder, given the known sensitivity to light in this
group (Barbini et al. 2005). A detailed description of the therapy
is available elsewhere (Sheaves et al. in press).
SC was delivered according to the national and local protocols
and guidelines. This typically included medication and contact
with full-time psychiatry, nursing, occupational therapy, social
work and health care assistant staff. A clinical psychologist offered
staff support and patient sessions 1 day per week. Patients were
invited to weekly multi-disciplinary ward round meetings.
Outcomes
The primary objective of the Oxford Ward sLeep Solution
(OWLS) was to assess the feasibility of trial procedures.
Feasibility outcomes included the percentage of patients admitted
to the ward who were recruited during the trial period, retention
of participants and uptake of the therapy. The primary efficacy
outcome measures were the ISI (Bastien et al. 2001) and the
WEMWBS(Tennant et al. 2007). Higher scores on the ISI indicate
more severe insomnia. The internal consistency (Cronbach’s α at
baseline) of the ISI in the present study was 0.78. Higher scores on
the WEMWBS indicate higher psychological wellbeing. The
internal consistency of the WEMWBS in the present study was
0.95.
Secondary efficacy outcome measures included interviewer-
rated assessments of psychiatric symptoms [Positive and
Negative Syndromes Scale (PANSS, Kay et al. 1987) and Young
Mania Rating Scale (YMRS, Young et al. 1978)]. The internal
consistency of these scales in the present study were PANSS posi-
tive 0.59, PANSS negative 0.60, PANSS general 0.62 and YMRS
0.66. Global distress was assessed via a ten 10- self-report measure
[Clinical Outcomes in Routine Evaluation, (CORE-10, Connell &
Barkham, 2007)]. The internal consistency of the CORE-10 in the
present study was 0.86. Suicidal ideation was assessed via the Beck
Suicide Scale (BSS, Beck et al., 1979). The internal consistency of
the BSS in the present study was 0.81.
Tertiary efficacy outcome measures included health-related
quality of life (EQ-5D) (The EuroQol Group, 1990). The internal
consistency of the EQ-5D in the present study was 0.56. Patient
satisfaction was assessed by an adapted version of the Client
Satisfaction Questionnaire (Larsen et al. 1979) at the end of the
therapy. Each item was rated on a five- point Likert scale.
Higher scores indicate higher satisfaction with therapy.
Provision of SC was monitored via medical records for each
patient using a modified version of the Client Service Receipt
Inventory (Beecham & Knapp, 1992). This included the duration
of admission between baseline and the 12-week assessment date
(taken from patients’ medical records) and medication at each
assessment. The defined daily dose (DDD) (World Health
Organization Collaborating Centre for Drug Statistics
Methodology, 2016) was used to convert all anti-psychotic,
mood stabiliser and anxiolytic medications into an equivalent
dose for each patient. The DDD is the gold standard measure
for comparing drug utilisation (World Health Organization
Collaborating Centre for Drug Statistics Methodology, 2016).
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The number of pro re nata (PRN, ‘taken when necessary’) medi-
cations prescribed were also measured across groups.
Serious adverse events (SAEs) were defined as (i) deaths, (ii)
suicide attempts, (iii) serious violent incidents, (iv) admissions
to secure units and (v) formal complaints about the therapy. If
the research team became aware of an adverse event, it was
reviewed and reported to the Oxford Health NHS Foundation
Trust Trial Safety Review Group (TSRG). This group is independ-
ent from the research team. The TSRG determined whether or not
the SAE was related to participation in the trial. Upon completion
of the trial, the medical records of all participants were reviewed
for SAEs, which had not been brought to the attention of the trial
team.
Statistical analysis
A detailed statistical analysis plan (SAP) was completed prior to
conducting the analysis. A sample size of 30 has been recom-
mended for use in pilot studies where the treatment effect is
expected to be large (Browne, 1995). Accounting for dropout,
we estimated that 50 participants would be required to meet the
Fig. 1. Flow diagram of trial participants.
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Table 1. Baseline demographics and clinical characteristics (N = 40)
Sleep treatment at acute crisis (n = 20) Standard care alone (n = 20)
Age (years) 40 (12) 40 (14)
Ethnicity
White British 12 (60%) 15 (75%)
White other 3 (15%) 3 (15%)
Mixed ethnic group 1 (5%) 1 (5%)
Asian 2 (10%) 1 (5%)
Black (African) 2 (10%) 0 (0%)
Marital status
Single 14 (70%) 13 (65%)
Married 4 (20%) 2 (10%)
Cohabiting 2 (10%) 1 (5%)
Divorced/separated 0 (0%) 4 (20%)
Employment status prior to admission
Unemployed 11 (55%) 9 (45%)
Registered sick 4 (20%) 4 (20%)
Employed full time 2 (10%) 4 (20%)
Student 2 (10%) 0 (0%)
Volunteer 0 (0%) 2 (10%)
Retired 1 (5%) 0 (0%)
Full-time carer 0 (0%) 1 (5%)
Accommodation status
No fixed abode (awaiting accommodation) 4 (20%) 6 (30%)
Living alone 5 (25%) 4 (20%)
Living with others 2 (10%) 5 (25%)
Living with parents 4 (20%) 1 (5%)
Living with spouse/partner 5 (25%) 2 (10%)
Living with other relatives 0 (0%) 2 (10%)
Diagnosis
Schizophrenia spectrum and other psychotic disorders 9 (45%) 9 (45%)
Affective disorders 11 (55%) 11 (55%)
Bipolar affective disorder 7 (35%) 4 (20%)
Depressive episode/disorder 4 (20%) 6 (30%)
Generalised anxiety disorder 0 (0%) 1 (5%)
Mental Health Act (1983) status at baseline
Informal admission 7 (35%) 4 (20%)
Section 2 (for assessment) 5 (25%) 8 (40%)
Section 3 (for treatment) 8 (40%) 8 (40%)
Insomnia severity (ISI)
Symptoms of insomnia (8–14) 6 (30%) 7 (35%)
Moderate insomnia (15–21) 9 (45%) 9 (45%)
Severe insomnia (22–28) 5 (25%) 4 (20%)
Wellbeing (WEMWBS) 39.8 (15.4) 42.3 (13.1)
(Continued )
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trial aims, as has been used in a previous study of insomnia treat-
ment for those with psychosis (Freeman et al. 2015).
Visual analysis of the histograms for the residuals of all efficacy
outcome measures was assessed and deemed sufficiently normal
for each subsequent analysis. Adjusted treatment difference and
confidence intervals were estimated using a linear mixed-effects
model, which accounts for repeated measures over time.
Baseline score of the outcome and the stratification variables
(diagnosis and baseline scores for insomnia and wellbeing) were
added as covariates in the model. Assessment point (weeks 2, 4
and 12), outcome of randomisation and an interaction between
assessment point and randomised group were included as fixed
effects to allow estimation of the treatment effect at the three
time points. Repeated measurements were accounted for by fitting
random intercepts for each participant. Given the objectives of
this pilot RCT, the analysis plan did not include reporting of p
values. A sensitivity analysis was planned for the primary efficacy
outcome measures, adding baseline duration of hospital
Table 1. (Continued.)
Sleep treatment at acute crisis (n = 20) Standard care alone (n = 20)
Chronotype (MEQ)
Moderate morning 3 (15%) 8 (40%)
Intermediate 11 (55%) 5 (25%)
Moderate evening 6 (30%) 7 (35%)
Number of previous admissions over past 5 years 0.6 (0.7) 1.1 (1.7)
Total number of days in hospital over past 5 years (median, IQR) 2.5 (0,21) 5.5 (0,49)
Duration of index admission up until baseline (median, IQR) 6 (4,26) 9 (5,18)
Data are: n (%) or mean (S.D.) unless otherwise indicated.
CBT, cognitive–behavioural therapy; ISI, Insomnia Severity Index; WEMWBS, Warwick-Edinburgh Mental Wellbeing Scale; MEQ, Morningness-Eveningness questionnaire.
Table 2. Use of standard National Health Service (NHS) care
n
Sleep treatment
at acute crisis n
Standard care
alone group
Contacts with community psychiatrist
6 months prior to baseline 20 4.4 (2.6) 20 4.4 (3.5)
Week 2 20 0.3 (0.7) 20 0.2 (0.5)
Week 4 20 0.2 (0.4) 20 0.3 (0.5)
Week 12 18 1.3 (2.2) 20 0.9 (1.8)
Contacts with care co-ordinator
6 months prior to baseline 20 6.9 (4.6) 20 6.9 (8.2)
Week 2 20 2.3 (4.2) 20 0.8 (0.8)
Week 4 20 1.5 (1.4) 20 1.2 (1.4)
Week 12 18 3.8 (4.6) 20 4.1 (2.3)
Contacts with psychologist (outside of the trial)
6 months prior to baseline 20 0.1 (0.3) 20 0.3 (0.7)
Week 2 20 0.5 (0.7) 20 0.4 (0.6)
Week 4 20 0.3 (0.6) 20 0.3 (0.5)
Week 12 18 0.2 (0.5) 20 0.5 (0.7)
Number of days attended day hospital
6 months prior to baseline 20 1.2 (1.7) 20 1.0 (3.1)
Week 2 20 0.7 (1.3) 20 0.1 (0.4)
Week 4 20 1.2 (2.2) 20 1.2 (2.2)
Week 12 18 1.3 (1.9) 20 2.7 (4.5)
Subsequent psychiatric inpatient admission within 12 weeks (i.e. relapse following discharge) 18 0 (0%) 20 1 (5%)
Data are mean (S.D.) or n (%).
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admission as a covariate. Sub-group analyses were pre-specified in
the SAP, to assess the impact of acute manic symptoms at baseline
on self-reported outcomes (online Supplementary material).
Owing to small sample sizes, these report descriptive statistics
only.
The duration of time in hospital was analysed using analysis of
covariance, given there was no repeated measurement. Baseline
duration in hospital and stratification factors (diagnosis and base-
line scores for insomnia and wellbeing) were added as covariates.
Standardised effect sizes are reported using Cohen’s d
(adjusted mean difference between groups/pooled baseline stand-
ard deviation). Analysis was conducted after the last trial assess-
ment was complete and followed intention-to-treat principles.
Analyses were conducted by BS using SPSS for windows version
23 (IBM Corp, 2015) and validated by a trial statistician (AN).
Results
Recruitment took place over 9 months (October 2015 to July
2016), with a 4-week break to account for therapist leave.
During the recruitment period, 40 patients were randomly allo-
cated to receive STAC in addition to SC (n = 20) or SC alone
(n = 20). The target of 50 patients was not reached owing to
lower throughput of patients on the ward. Figure 1 shows the
flow of participants through the trial. All 40 participants com-
pleted the baseline and 2-week assessments (primary end
point). Thirty-four participants completed all assessments
(weeks 0, 2, 4 and 12) for the primary efficacy measures (85%).
One participant dropped out at week 4 and a further five dropped
out at the week 12 assessment (Fig. 1). In the STAC group, all par-
ticipants (n = 20, 100%) completed the intervention. The mean
number of treatment sessions received across the 14-day therapy
window was 8.6 (S.D. = 1.5) and the mean duration of sessions
was 44.8 min (S.D. = 15.6). No more than one therapy session
was offered in a day and the aim was to provide more sessions
in week 1 of the therapy and taper sessions in week 2. Across
the STAC group, 171 sessions were attended out of 187 offered
(91.4%). Of the 16 sessions not attended, 10 (62.5%) were due
to service-related factors (e.g. clashes with tribunals, Mental
Health Act assessments or with escorted leave availability) and
six (37.5%) were due to patient factors (e.g. the patient feeling
too unwell to attend).
Baseline and clinical characteristics were largely similar across
the two randomised groups (Table 1). The average age was 40
years, similar to other studies recruiting those with severe mental
illnesses (Freeman et al. 2015; Harvey et al. 2015). Most partici-
pants were single, unemployed prior to admission, detained
under a section of the Mental Health Act (1983) and a quarter
had no current accommodation. With regards to chronotype,
there were a higher number of patients in the SC group who
fell into the ‘moderate morning’ group, and more patients in
the STAC group who fell into the ‘intermediate’ chronotype
group.
Provision of SC (Table 2) and prescribed medication (Table 3)
were similar at all assessment points. Polypharmacy was the
norm; the mean number of medications was similar across both
groups at baseline (mean = 2.5, S.D. = 1.3 for the STAC group
and mean = 2.3, S.D. = 1.1 for the SC group). This reduced margin-
ally by the 12-week assessment (mean = 2.1, S.D. = 1.1 for the
STAC group and mean = 2.0, S.D. = 1.1 in the SC group). At base-
line, less than half of the participants were prescribed PRN hyp-
notic medication (STAC group n = 7, SC alone group n = 6). At
week 2, five patients in each trial group were prescribed PRN
medications. This decreased by the 4-week assessment (STAC
group n = 4, SC alone group n = 3) and again at the 12-week
assessment (STAC group n = 0, SC alone group n = 1). All PRN
medications are reported in online Supplementary Table S1.
Primary efficacy outcomes
The STAC group had a treatment benefit in the large effect size
range at 2 weeks (Table 4), compared with SC. At 4 weeks, the
treatment still conferred a benefit, in the medium effect size
range when compared with SC alone.
At week 0, all patients’ ISI scores indicated clinically significant
insomnia symptoms (ISI ⩾ 8). By week 2, eight participants in the
STAC group reported no clinically significant insomnia symp-
toms (40%) compared with four in the SC alone group (20%).
A small treatment effect was found on psychological wellbeing
at all time points when compared with SC alone. Wide confidence
intervals for this effect include the possibility that STAC may
increase or decrease psychological wellbeing. Results of the
Table 3. Medication use over time
Sleep treatment at
acute crisis (n = 20)
Standard care
alone (n = 20)
Number of medications
Week 0 2.5 (1.3) 2.3 (1.1)
Week 2 2.6 (1.2) 2.3 (1.1)
Week 4 2.5 (1.5) 2.2 (1.2)
Week 12 2.1 (1.1) 2.0 (1.1)
Defined daily dose of anti-psychotics
Week 0 1.5 (1.9) 0.9 (0.7)
Week 2 1.6 (1.9) 1.5 (2.0)
Week 4 1.0 (0.6) 1.0 (0.6)
Week 12 1.4 (1.3) 1.1 (0.6)
Defined daily dose of mood stabilisers
Week 0 0.3 (0.1) 0.1 (0.2)
Week 2 0.3 (0.6) 0.1 (0.2)
Week 4 0.2 (0.2) 0.1 (0.2)
Week 12 0.2 (0.5) 0.1 (0.3)
Defined daily dose of anxiolytics
Week 0 0.1 (0.2) 0.1 (0.2)
Week 2 0.3 (0.7) 0.1 (0.3)
Week 4 0.2 (0.7) 0.1 (0.3)
Week 12 0.0 (0.1) 0.1 (0.2)
Defined daily dose of anti-depressants
Week 0 0.6 (1.3) 0.9 (1.4)
Week 2 0.9 (1.6) 1.1 (1.6)
Week 4 0.8 (1.5) 1.0 (1.4)
Week 12 0.9 (1.6) 1.0 (1.4)
Defined daily dose = a gold standard equivalence measure of drug utilisation (World Health
Organization Collaborating Centre for Drug Statistics Methodology, 2016).
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sensitivity analysis on both insomnia and wellbeing (online
Supplementary Table S2) showed a similar pattern of results.
Planned sub-group analyses (online Supplementary Table S3)
revealed that patients presenting with manic symptoms at base-
line, and hence elevated baseline wellbeing, may have reduced
the treatment effects for wellbeing.
Secondary efficacy outcomes
For secondary outcomes (Table 5), the effect sizes, in general,
were in the direction of STAC improving assessment scores.
However, the wide confidence intervals for each variable cover a
range from STAC potentially increasing or decreasing scores on
psychiatric symptoms (YMRS rated mania, PANSS positive, nega-
tive and general psychopathology and suicidal ideation) and dur-
ation of admission, when compared with SC alone. Global distress
had a small treatment effect at 2 weeks, which was maintained at 4
weeks. By 12 weeks, the SC alone group had scores similar to the
treatment group.
There was one SAE in the STAC group, a suicide attempt. This
was deemed by the TSRG to be unrelated to participation in the
study.
Eighty per cent (16 out of 20) of the participants who received
therapy returned the Client Satisfaction Questionnaires (online
Supplementary Table S4). Scores indicate a high level of satisfac-
tion by the majority of participants. Nine of the 16 rated their
overall satisfaction as ‘very satisfied’ and seven out of 16 rated
their overall satisfaction as ‘mostly satisfied’. With regards to
health-related quality of life (EQ-5D), there was a treatment bene-
fit in the small effect size range for the STAC group when com-
pared with SC. This was not maintained at follow-up (online
Supplementary Table S5).
Discussion
This is the first RCT of a psychological treatment for insomnia on
an acute psychiatric inpatient ward setting. In this challenging
environment for research, it was found that it is feasible to run
an RCT of a psychological insomnia intervention. Despite
experiencing acute psychiatric symptoms, participants were
recruited with informed consent, completed assessments, were
randomly allocated to two arms of the trial and the follow-up
rate for assessments was high, even at 12 weeks when the majority
of patients were discharged home. The rate of both uptake and
completion of the therapy was 100% and patient satisfaction
with the therapy was high.
Findings show that STAC may be highly beneficial for treating
insomnia, with associated reductions in global distress at 2 weeks
when compared with SC alone. Whilst the SC alone group showed
improvement in insomnia across the 12-week assessment period,
STAC led to a quicker and potentially fuller recovery from insom-
nia. The small effect on psychological wellbeing is promising.
However, wide confidence intervals for the treatment effect
include the possibility that there is no impact on wellbeing.
Sub-group analysis revealed that patients with manic symptoms
who had particularly elevated baseline wellbeing scores, which
subsequently decreased, may have lessened the effect.
Providing psychological treatment for insomnia on an
inpatient setting is a radical shift of focus. Sleep problems are per-
vasive on inpatient wards, despite the sedative effects of multiple
medications (Waters et al. 2012), which is the common service
response to patient reports of sleep difficulties (Rehman et al.
2016). The insomnia treatment produced a faster recovery than
SC alone. ISI scores at week 2 for those who received the sleep
treatment were equivalent to week 12 scores in the SC group.
These results from an inpatient setting add to a growing body
of research showing that it is feasible to treat sleep problems in
patients with psychosis (Freeman et al. 2015) and bipolar affective
disorder (Harvey et al. 2015) and, recently, patients at risk of
psychosis (Bradley et al. in press).
Importantly, the therapy was also acceptable to the inpatient
group: every patient who was offered STAC completed the full
course of the therapy. The rationale of the study was that ‘when
people sleep better, they tend to feel better’. We think this intuitive
understanding of the importance of good sleep facilitated engage-
ment, irrespective of insight into psychiatric symptoms. The
intensive style of the therapy, providing an average of nine ses-
sions over a 2-week period, was beneficial for supporting patients
Table 4. Scores for primary efficacy outcome measures
Sleep treatment
at acute crisis (n = 20)
Standard
care (n = 20)
Adjusted mean difference
between groups (95% CI)
Between-group standardised
effect size (d)
Primary efficacy outcome measures
Insomnia (ISI)
Week 0 17.1 (6.0) 16.1 (4.9)
Week 2 8.5 (5.4) 12.5 (5.5) −4.6 (−7.7 to −1.4) −0.9
Week 4 6.8 (5.2) 10.1 (5.6) −3.6 (−7.0 to −0.3) −0.7
Week 12 5.8 (4.9) 8.6 (4.4) −2.8 (−6.3 to 0.7) −0.5
Wellbeing (WEMWBS)
Week 0 39.8 (15.4) 42.3 (13.1)
Week 2 47.4 (10.5) 44.8 (13.4) 3.7 (−2.8 to 10.1) 0.3
Week 4 48.3 (11.7) 45.6 (10.3) 3.6 (−2.8 to 9.9) 0.3
Week 12 48.3 (12.3) 44.4 (12.9) 4.3 (−4.1 to 12.7) 0.3
Data are mean (S.D.).
ISI, Insomnia Severity Index; WEMWBS, Warwick–Edinburgh Mental Wellbeing Scale.
All analyses controlled for stratification factors (insomnia severity, wellbeing and diagnosis).
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to try out new techniques. This intensity of the therapy may be
particularly beneficial for sleep problems, whereby the sleep
plan can be optimised each night in light of the previous night’s
sleep. The addition of sleep monitoring devices was both
informative for the sleep plan and a way of acknowledging posi-
tive change to build patient motivation and self-efficacy.
It is possible that the therapy may have wider benefits beyond
sleep, for example, the group that received STAC were discharged
Table 5. Scores for secondary efficacy outcome measures
Sleep treatment at
acute crisis (n = 20)
Standard care
(n = 20)
Adjusted mean difference
between groups (95% CI)
Between-group standardised
effect size (d)
Positive symptoms (PANSS)
Week 0 15.3 (6.6) 15.4 (5.2)
Week 2 12.2 (4.8) 12.5 (4.6) 0.2 (−2.1 to 2.4) 0.0
Week 4 11.2 (3.9) 11.2 (4.3) 0.1 (−2.1 to 2.4) 0.0
Week 12 9.4 (2.9) 10.4 (3.5) −0.4 (−3.0 to 2.3) −0.1
Negative symptoms (PANSS)
Week 0 14.7 (6.0) 13.9 (4.3)
Week 2 12.8 (4.1) 13.8 (5.7) −1.4 (−4.3 to 1.4) −0.3
Week 4 11.9 (4.6) 13.6 (5.1) −2.0 (−5.3 to 1.2) −0.4
Week 12 11.9 (3.5) 14.9 (7.4) −3.7 (−7.8 to 0.3) −0.7
General psychopathology (PANSS)
Week 0 38.4 (9.2) 39.2 (8.3)
Week 2 31.4 (6.6) 34.7 (8.5) −3.1 (−7.2 to 1.1) −0.4
Week 4 30.8 (8.8) 30.2 (8.0) 0.8 (−3.8 to 5.5) 0.1
Week 12 29.1 (8.4) 30.5 (11.8) −0.4 (−7.3 to 6.5) −0.1
PANSS total
Week 0 68.3 (16.3) 68.4 (14.9)
Week 2 56.4 (9.2) 61.1 (15.5) −4.4 (−11.5 to 2.8) −0.3
Week 4 53.9 (12.6) 54.9 (14.7) −1.2 (−9.8 to 7.4) −0.1
Week 12 50.4 (11.7) 55.8 (19.0) −4.4 (−15.2 to 6.4) −0.3
Manic symptoms (YMRS)
Week 0 14.6 (9.8) 13.9 (6.2)
Week 2 9.4 (6.8) 11.2 (6.6) −1.1 (−5.0 to 2.7) −0.1
Week 4 8.1 (8.3) 7.8 (6.4) 0.0 (−4.4 to 4.4) 0.0
Week 12 5.4 (6.4) 7.8 (6.7) −1.8 (−6.2 to 2.6) −0.2
Global distress (CORE-10)
Week 0 19.9 (8.4) 17.2 (9.9)
Week 2 10.4 (5.6) 13.3 (7.4) −3.7 (−6.9 to −0.5) −0.4
Week 4 9.9 (6.4) 10.9 (6.6) −1.9 (−5.0 to 1.2) −0.2
Week 12 11.7 (8.0) 11.3 (6.2) 0.4 (−3.4 to 4.2) 0.0
Suicidal ideation (BSS)
Week 0 4.6 (8.3) 6.7 (10.1)
Week 2 0.8 (3.3) 3.6 (8.7) −1.8 (−5.0 to 1.5) −0.2
Week 4 1.1 (4.6) 3.0 (6.9) −0.7 (−3.6 to 2.3) −0.1
Week 12 1.3 (3.5) 2.0 (5.9) 0.4 (−3.3 to 4.2) 0.0
Duration of admission in days (baseline to 12 weeks) 32.5 (22.9) 37.9 (25.1) −5.8 (−21.6 to 10.0) −0.2
Duration of admission (baseline to discharge) 33.5 (25.6) 41.0 (33.7) −8.5 (−28.0 to 11.1) −0.3
Data are mean (S.D.).
PANSS, Positive and Negative Syndromes Scale; YMRS, Young Mania Rating Scale; CORE-10, Clinical Outcomes in Routine Evaluation, 10-item scale; BSS, Beck Suicide Scale.
All analyses controlled for baseline score for that variable and stratification factors (insomnia severity, diagnosis and wellbeing).
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from hospital over a week (8.5 days) earlier than the SC group.
However, the wide confidence intervals for the treatment effect
include the possibility that there is no impact on length of admis-
sion. The trial was designed as a pilot study and hence the pri-
mary objective was to assess the feasibility of trial procedures,
rather than assessing efficacy. A larger trial is now indicated, pow-
ered to detect plausible secondary effects of stabilising sleep.
A potential limitation of the trial is that it did not include
objective measures of sleep (e.g. actigraphy or polysomnography)
or relevant co-morbid sleep disorders (e.g. sleep apnoea or night-
mare disorder). Our priority was to minimise assessment time and
hence prioritise recruitment and retention of participants.
Objective sleep assessments may also be less suitable for an
inpatient group. Actigraphy infers sleep from a period of inactivity.
Its accuracy for those with psychosis, who may be awake but
inactive, has therefore been questioned (Freeman et al. 2015).
Polysomnography involves sensors on the patient with connecting
wires to transmit data. This equipment may pose a ligature risk
and also further exacerbate sleep disruption. The male and pre-
dominantly white British sample may limit generalisability of
results. A future study should recruit a more diverse group of inpa-
tients. Given the potential causal association between insomnia
and negative affect (Freeman et al. 2017), a future study may
choose to include validated self-report measures of depression
and anxiety. We compared the sleep treatment (in addition to
SC) with SC alone, rather than an active control (e.g. befriending).
This does not rule out the possibility that the efficacy effects are the
result of unspecific aspects of the intensive therapy, rather than the
STAC techniques specifically. Given this was a pilot RCT, our aim
was to determine feasibility and collect initial efficacy data, rather
than assessing what elements of the treatment produce change.
The clear next step is a definitive trial powered to assess the efficacy
of the intervention and the possible impact on both psychiatric
symptoms and length of hospitalisation. If replicated, this inher-
ently collaborative treatment approach for sleep could mark a rad-
ical shift of focus for psychiatric inpatient wards.
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